Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade

Xianli Jiang, Nils-Petter Rudqvist, Bo Jiang, Shengbin Ye, Yang Zi, Qingnan Liang, Jinzhuang Dou, Michelle D. Williams, Joe Dan Dunn, Jason M. Johnson, Keiko Akagi, Weihong Xiao, Shaoheng Liang, Satvik Elayavalli, Baohua Sun, Edwin R. Parra, Renata Ferrarotto, Adam S. Garden, Clifton D. Fuller, Jay P. Reddy, Neil D. Gross, Miriam N. Lango, Cheuk Hong Leung, Suyu Liu, Diane Liu, J. Jack Lee, Michael A. Curran, Jack Phan, Ken Chen, Maura L. GillisonmedRxiv 2024 · DOI

Abstract

In a phase 2 clinical trial (NCT03799445), patients with local-regionally advanced HPV-positive oropharyngeal carcinoma (OPC) were treated with a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) as induction immunotherapy followed by concurrent radiotherapy. The study achieved its co-primary endpoints, including a 94% complete metabolic response rate at six months and an 84% progression-free survival rate at two years. Notably, induction therapy alone yielded a 46% major histological response (MHR) rate. High-resolution single-cell profiling revealed that responders possessed higher baseline levels of intratumoral tissue-resident memory (TRM) CD8+ T cells and NK cells expressing FCGR3A. A significant decrease in effector regulatory T (eTreg) cells—which highly express CTLA4—was observed exclusively in responders, suggesting an ipilimumab-dependent depletion mechanism mediated by FCGR3A+ NK cells. This depletion correlated with an increase in IFNG+ effector CD8+ T cells. These findings indicate that the targeted depletion of eTregs is a critical driver of clinical response in dual immune checkpoint blockade.

Introduction

Human papillomavirus-positive oropharyngeal carcinoma (HPV+ OPC) represents a distinct clinical entity with a generally favorable prognosis compared to HPV-negative cases. However, the standard of care—intensive chemoradiotherapy—is associated with significant long-term toxicity. While immune checkpoint blockade (ICB) has transformed the treatment landscape for recurrent and metastatic disease, its role in the neoadjuvant or induction setting for newly diagnosed patients remains under investigation.

A central debate in the field concerns the mechanism of anti-CTLA-4 therapy: does it function primarily by "releasing the brakes" on effector T cells, or by actively depleting the immunosuppressive regulatory T cells (Tregs) that protect the tumor? This study utilizes longitudinal single-cell analysis from the INVAX trial to resolve this question, mapping the cellular dynamics that dictate success or failure in dual ICB therapy.

Methods and Study Design

The researchers conducted the Phase 2 INVAX trial, enrolling 37 patients with advanced HPV+ OPC. Patients received a six-week induction course of ipilimumab and nivolumab prior to radiotherapy. To dissect the immune response, the team employed a multi-omic approach:

  • Single-cell RNA and TCR Sequencing: The study profiled 367,451 individual cells from 64 longitudinal tumor biopsies (baseline and mid-induction), providing a high-resolution map of the tumor immune microenvironment (TIME).
  • Predictive Modeling: LASSO regression was used to identify baseline immune features that could predict a reduction in tumor viability.
  • Biomarker Monitoring: Plasma cell-free HPV DNA (cfHPV) was tracked as a sensitive indicator of minimal residual disease.
  • Functional Validation: Jurkat cells were engineered with patient-derived T-cell receptors (TCRs) to confirm the recognition of HPV-specific antigens.

Key Results

Clinical Efficacy and Molecular Clearance

The induction regimen demonstrated remarkable clinical activity. After only six weeks of dual ICB, 46% of patients achieved a major histological response (MHR), defined as less than 10% viable tumor remaining. The 2-year progression-free survival (PFS) stood at 84.4%, and the 6-month complete metabolic response rate was 94.3%. Furthermore, 71.4% of responders showed complete clearance of plasma cfHPV during the induction phase, often before the initiation of radiotherapy.

The NK-eTreg Axis

Single-cell analysis identified a specific subset of Natural Killer (NK) cells expressing FCGR3A (CD16) as the primary predictor of response. These cells are capable of Antibody-Dependent Cellular Cytotoxicity (ADCC). The data suggests that these NK cells utilize the anti-CTLA-4 antibody (ipilimumab) as a homing beacon to target and deplete effector Tregs (eTregs), which express high levels of CTLA-4. This depletion was observed only in patients who responded to therapy, whereas non-responders maintained their eTreg populations.

T-Cell State Transitions

The study highlighted the importance of a pre-existing "reservoir" of tissue-resident memory (TRM) CD8+ T cells. In responders, these TRM cells transitioned into active, IFNG+ effector cells following eTreg depletion. Conversely, in non-responders, T-cell clones either remained stagnant or transitioned toward a state of terminal exhaustion and unproductive proliferation.

Discussion

These findings provide strong evidence that the efficacy of dual ICB in HPV+ OPC is heavily dependent on the physical depletion of eTregs rather than a simple functional reprogramming. The correlation between baseline FCGR3A+ NK cells and subsequent eTreg loss suggests that the innate immune system plays a foundational role in enabling the adaptive T-cell response.

While the study is limited by its relatively small cohort and the use of core needle biopsies, the depth of the single-cell data offers a compelling mechanistic framework. Future therapeutic strategies may benefit from optimizing NK-mediated ADCC to ensure the robust removal of intratumoral suppression, thereby unlocking the full potential of resident T-cell populations. This study reinforces the potential for de-escalated treatment strategies in HPV+ OPC by identifying the specific cellular signatures of a successful immune response.

Summary updated

Abstract

ABSTRACT In a phase 2 trial, local-regionally advanced HPV-positive oropharyngeal carcinoma (OPC) patients received ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) as induction immunotherapy and concurrently with radiotherapy ( NCT03799445 ). Co-primary endpoints achieved included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% major histological response rate. Single-cell profiling revealed responders had higher baseline intratumoral tissue-resident memory (TRM) CD8 + T cells and NK cells expressing Fc Gamma Receptor IIIa ( FCGR3A ). Decreases in effector regulatory T (eTreg) cells, which highly expressed CTLA4 , occurred only in responders, suggesting ipilimumab-dependent depletion by FCGR3A + NK cells. eTreg depletion correlated with increased Interferon Gamma ( IFNG ) + effector CD8 + T cells. CD8 + T-cell clonotypes transitioned from TRM to effector memory and IFNG + effector cells in responders, whereas clonotypes transitioned to exhausted TRM and proliferating cells in nonresponders. We conclude that eTreg depletion is critical for major response to induction dual immune checkpoint blockade.
BibTeX
@misc{jiang2024depletion,
  author = {Xianli Jiang and Nils-Petter Rudqvist and Bo Jiang and Shengbin Ye and Yang Zi and Qingnan Liang and Jinzhuang Dou and Michelle D. Williams and Joe Dan Dunn and Jason M. Johnson and Keiko Akagi and Weihong Xiao and Shaoheng Liang and Satvik Elayavalli and Baohua Sun and Edwin R. Parra and Renata Ferrarotto and Adam S. Garden and Clifton D. Fuller and Jay P. Reddy and Neil D. Gross and Miriam N. Lango and Cheuk Hong Leung and Suyu Liu and Diane Liu and J. Jack Lee and Michael A. Curran and Jack Phan and Ken Chen and Maura L. Gillison},
  title = {{Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade}},
  year = {2024},
  doi = {10.1101/2024.01.04.23300616},
  howpublished = {medRxiv},
}
Figure